GeNeuro (BATS-CHIXE:GNROP) - Stock Price, News & Analysis

GNROP Stock Overview

A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.

About the company

GNROP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Negative shareholders equity

Earnings have declined by 8.6% per year over past 5 years

Does not have a meaningful market cap (€3M)

Makes less than USD$1m in revenue (€0)

+ 2 more risks

GeNeuro SA Competitors

ValiRx

AIM:VAL

UK£1.9m

Theracryf

AIM:TCF

UK£3.2m

LungLife AI

AIM:LLAI

UK£3.5m

BSF Enterprise

LSE:BSFA

UK£3.9m

Price History & Performance

Summary of all time highs, changes and price drops for GeNeuro
Historical stock prices
Current Share Price	€0.071
52 Week High	€0.071
52 Week Low	€0.071
Beta	0.37
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-97.51%

Recent updates

Shareholder Returns

	GNROP	GB Biotechs	GB Market
7D	n/a	4.7%	1.4%
1Y	n/a	-16.4%	8.1%

Return vs Industry: Insufficient data to determine how GNROP performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how GNROP performed against the UK Market.

Price Volatility

Is GNROP's price volatile compared to industry and market?
GNROP volatility
GNROP Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: GNROP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GNROP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	17	Jesus Martin-Garcia	www.geneuro.com

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301.

GeNeuro SA Fundamentals Summary

How do GeNeuro's earnings and revenue compare to its market cap?
GNROP fundamental statistics
Market cap	€2.53m
Earnings (TTM)	-€14.76m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is GNROP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNROP income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€14.76m
Earnings	-€14.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.50
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-93.4%

How did GNROP perform over the long term?

See historical performance and comparison

GNROP Stock Overview

Rewards

Risk Analysis

GeNeuro SA Competitors

AIM:VAL

UK£1.9m

AIM:TCF

UK£3.2m

AIM:LLAI

UK£3.5m

LSE:BSFA

UK£3.9m

Price History & Performance

Recent News & Updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

Recent updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Insufficient new directors

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Insufficient new directors

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Shareholder Returns

Price Volatility

About the Company

GeNeuro SA Fundamentals Summary

0.0x

-0.2x

Earnings & Revenue